| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-03-31 | Acacia Pharma (UK) | $10 million (€7 million) | Series A financing round | Lundbeckfond Ventures (Denmark) - Gilde Healthcare (The Netherlands) | Cancer - Oncology | Fundraising |
| 2011-03-31 | BioVersys (Switzerland) | CHF 2.5 millions (€1.9 million) | seed financing round | EVA (Switzerland) - BioValley Business Angels Club BioBAC (Switzerland) | Infectious diseases | Fundraising |
| 2011-03-31 | to-BBB (The Netherlands) | €1.2 million | government loan | Agentschap NL (The Netherlands) | Cancer - Oncology | Subvention |
| 2011-03-30 | Galapagos (Belgium) | €469,263.67 | capital increase arising from employee warrant exercises | employees | Capital increase | |
| 2011-03-28 | Anergis (Switzerland) | CHF 18 million (€ 13,8 million) | Series A financing round | Vinci Capital-Renaissance PME (Switzerland) BioMedInvest (Switzerland) Sunstone Capital ( Denmark) Esperante (Sweden) Initiative Capital Romandie (Switzerland) private investors |
Allergic diseases - Immunological diseases | Series A financing round |
| 2011-03-22 | Zealand Pharma (Denmark) Pepscan Therapeutics (The Netherlands) | €0.86 million | grant | European Eurostars Programme (EU) | Inflammatory diseases | Grant |
| 2011-03-14 | Activiomics (UK) | £500,000 (€578 000) | funding round | IP Group (UK) - IP Venture Fund, (a venture capital fund managed by IP Group) - members of Activiomics' management | Cancer - Oncology - Technology - Services | Fundraising |
| 2011-03-11 | Biotie Therapies (Finland) | €27 million | private placement | Finnish and international institutional and strategic investors. | Neurodegenerative diseases - Mental diseases | Private placement |
| 2011-03-08 | Cellectis (France) Etablissement Français du Sang (EFS) (France) Pierre and Marie Curie University (UPMC) (France) Bertin Technologies (France) | €9.3 million | grant | OSEO (France) | Technology - Services | Grant |
| 2011-03-03 | Bioalliance Pharma and a consortium of laboratories and companies (France) | € 2 million including €743,000 specifically allocated to BioAlliance Pharma. | grant | FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France) | Infectious diseases | Grant |
| 2011-02-28 | Arsanis (USA - MA) | $10 million | series A financing round | OrbiMed Advisors (USA - NY) Polaris Venture Partners (USA - MA) SV Life Sciences (UK - USA) | Infectious diseases | Series A financing round |
| 2011-02-25 | Tigenix (Belgium) | €15 million | private placement | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Private placement | |
| 2011-02-23 | 4SC (Germany) | capital increase | Autoimmune diseases - Cancer - Oncology | Private placement | ||
| 2011-02-23 | Intercell (Austria) | € 33 million | private placement | international institutional investors | Infectious diseases | Private placement |
| 2011-02-23 | Neurotune (Switzerland) and consortium of research team in the DISARCO project | €720,000 | grant | European Eurostars Programme (EU) | Grant | |
| 2011-02-22 | VitamFero (France) | €1.1 million | seed capital | CapDecisif Management (France) G1J Ile-de-France (France) | Infectious diseases | Fundraising |
| 2011-02-22 | Beactica (Sweden) | €700 000 | grant | Infectious diseases | Grant | |
| 2011-02-22 | Vironova (Sweden) | €6 million | grant | European Commission’s Seventh Framework Program (FP7) | ||
| 2011-02-22 | Vironova (Sweden) | €6 million | grant | Infectious diseases | Grant | |
| 2011-02-22 | Vitamfero (France) | € 1.1 million | financing round | CapDecisif Management (France) G1J Ile-de-France (France) |
